No Data
Shanghai Shyndec Pharmaceutical Co., Ltd.'s (SHSE:600420) Market Cap Surged CN¥738m Last Week, Private Companies Who Have a Lot Riding on the Company Were Rewarded
Shanghai Shyndec Pharmaceutical (600420.SH): Finasteride tablets pass generic drug consistency evaluation
格隆汇 November 5th, shanghai shyndec pharmaceutical (600420.SH) announced that the company has received the Approval Notice for Supplementary Application for Drugs issued by the National Medical Products Administration, approving the approval of Finasteride Tablets through the evaluation of generic drug quality and efficacy consistency. Finasteride is a 4-azasteroid hormone compound that can inhibit prostate hyperplasia by reducing dihydrotestosterone levels in blood and prostate tissue, improve related clinical symptoms of benign prostatic hyperplasia. Finasteride tablets (1mg) are used to treat male pattern baldness (androgenetic alopecia), promoting hair growth and preventing further hair loss. Finasteride tablets (5mg).
Sinopharm Hyundai: third quarter report 2024
Third Quarter Report 2024
Shanghai Shyndec Pharmaceutical (SHSE:600420) Has A Rock Solid Balance Sheet
Voluntary Disclosure Notice for Earnings Forecast for the First Three Quarters of 2024
No Data
No Data